Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$146.01 USD
-0.83 (-0.57%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $143.59 -2.42 (-1.66%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
Quest Diagnostics (DGX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$149.87 | $165.00 | $130.00 | 2.06% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Quest Diagnostics comes to $149.87. The forecasts range from a low of $130.00 to a high of $165.00. The average price target represents an increase of 2.06% from the last closing price of $146.84.
Analyst Price Targets (15)
Broker Rating
Quest Diagnostics currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 2.47 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, five are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 26.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/DGX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 10 | 10 | 11 | 11 | 11 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.33 | 2.33 | 2.47 | 2.47 | 2.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | Truist Securities | David S Macdonald | Hold | Hold |
7/10/2024 | Not Identified | Not Identified | Hold | Strong Buy |
4/29/2024 | Robert W. Baird & Co. | Eric W Coldwell | Hold | Hold |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/24/2024 | UBS | Kevin Caliendo | Hold | Hold |
4/23/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
2/8/2024 | Piper Sandler | David M Westenberg | Hold | Hold |
2/7/2024 | Not Identified | Not Identified | Hold | Strong Buy |
2/1/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
10/11/2023 | Evercore Partners | Elizabeth Anderson | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 15 |
Average Target Price | $149.87 |
LT Growth Rate | 5.20% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 63 of 252 |
Current Quarter EPS Est: | 2.31 |